Novartis Global study endorsed* by EHDN

Study aims and goal: A Randomized, double-blind, placebo-controlled dose range finding study with Open-Label Extension to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LMI070/branaplam in participants with early manifest HD.
No. of study sites: This Phase IIb study aims to recruit stage 1 and 2 participants at sites in Belgium, Canada, France, Germany, Hungary, Italy, Lithuania, Russia, Spain, UK and USA.
For further information see the website: (link will be posted when available)